Generic Sovaldi 400 mg Hepcinate Sofosbuvir
|28 pills - 2678.57 EURO (95.66 EURO/pill) ||Add to cart|
|56 pills - 5267.86 EURO (94.07 EURO/pill) ||Add to cart|
|84 pills - 7767.86 EURO (92.47 EURO/pill) ||Add to cart|
|Manufactured by: Natco Pharma- India|
Dosage: 400 mg
For large orders the Registered Mail shipping fee will be applied for each 100 pills.
For order more then 300 pills or bulk orders, please, contact [email protected] in order to have a special price.
Shipped from: UK
|For this product we can accept payments only by bank transfer or Western Union because card processors cannot accept such big amounts. To buy it, please contact us at [email protected] This product will be shipped by courier, delivery 4/5 days.
Sovaldi (Sofosbuvir) is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.
Sovaldi (Sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, among the second generation of protease inhibitors that directly attack the Hep C virus cell.
These are the highlights of Sovaldi (Sofosbuvir):
* A 400mg tablet, once-daily oral dose. *See below for recommended regimens.
*Sovaldi (Sofosbuvir) approved for use in Genotypes 1, 2, 3, or 4
*High Cure Rates with an overall response rate of 90% in most gentotypes.
*Shortened 12 Week Course of Therapy for Many Patients.
*First Ever Oral Treatment Regimen for Genotypes 2 or 3. *See below for recommended regimens.
*First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence.
Recommended regimens and treatment duration for Sovaldi (Sofosbuvir) combination therapy in HCV mono-infected or HCV/HIV-1 co-infected patients follows:
Genotype 1 or 4
Treatment: Sovaldi (Sofosbuvir) + Peg-interferon alfa + ribavirin
Duration: 12 weeks
Treatment: Sovaldi (Sofosbuvir) + ribavirin
Duration: 12 weeks
Treatment: (Solvaldi Sofosbuvir) + ribavirin
Duration: 24 weeks
Sovaldi (Sofosbuvir) can be considered for (CHC) chronic hepatitis C patients with genotype 1 infection in combination with ribavirin for 24 weeks for those patients who are interferon ineligible.
Additionally, Sovaldi (Sofosbuvir) should be used in combination with ribavirin for treatment of CHC patients with hepatocelluar carcinoma (liver cancer) awaiting liver transplantation for up to 48 weeks or until liver transplant to prevent post-transplant HCV infection.
Treatment regimen, duration and response to Sovaldi (Sofosbuvir) are dependent on viral genotype and patient population, and associated baseline factors. Monotherapy is not recommended.
The current standard treatment for HCV can involve up to 48 weeks of therapy with a peglated interferon (peg-IFN), ribavirin (RBV)-containing regimen and in some genotypes used with one of the first class of protease inhibitors approved by the FDA in 2011, telaprevir (Incivek) and boceprevir (Victrelis).
Side effects of Sovaldi (Sofosbuvir) Most Common:
Sovaldi +peginterferon alfa + ribavirin combination therapy were fatigue, headache, nausea, insomnia, and anemia.
Sovaldi +ribavirin combination therapy were fatigue and headache.
Drug Interactions with Sovaldi:
In addition to rifampin and St. Johnís wort, coadministration of Sovaldi is not recommended with carbamazepine, oxcarbazepine, Phenobarbital, phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease the concentration of Sofosbuvir, reducing its therapeutic effect.